AbbVie announced that the independent directors of the board have selected Roxanne Austin as lead independent director, effective July 1. Austin succeeds Glenn Tilton, who has served as lead independent director since 2013. Tilton will continue to serve on the AbbVie Board as an independent director.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: FDA approves SKYRIZI for ulcerative colitis
- AbbVie price target raised to $190 from $185 at Piper Sandler
- AbbVie Recommends Shareholders Reject Tutanota’s “Mini-Tender” Offer
- AbbVie recommends shareholders reject Tutanota’s ‘mini-tender’ offer
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential